Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

435 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma.
Saeki I, Suehiro Y, Yamauchi Y, Hoshida T, Tanabe N, Oono T, Kawamoto D, Nishimura T, Matsumoto T, Ishikawa T, Shimokawa M, Tamori A, Kawada N, Tamai Y, Iwasa M, Nakagawa H, Nagano H, Takami T, Yamasaki T. Saeki I, et al. Among authors: shimokawa m. Hepatol Int. 2023 Oct;17(5):1289-1299. doi: 10.1007/s12072-023-10488-y. Epub 2023 Apr 25. Hepatol Int. 2023. PMID: 37186217
Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study).
Suzuki N, Hazama S, Nagasaka T, Tanioka H, Iwamoto Y, Negoro Y, Yamauchi M, Kobayashi M, Okuda H, Fujishima N, Nishimura T, Yamanaka N, Toyota K, Mori Y, Nakagami Y, Shimokawa M, Nagano H, Okajima M. Suzuki N, et al. Among authors: shimokawa m. Int J Clin Oncol. 2019 Oct;24(10):1223-1230. doi: 10.1007/s10147-019-01473-3. Epub 2019 May 29. Int J Clin Oncol. 2019. PMID: 31144145 Free PMC article. Clinical Trial.
Clinicopathologic features, treatment, prognosis and prognostic factors of neuroendocrine carcinoma of the endometrium: a retrospective analysis of 42 cases from the Kansai Clinical Oncology Group/Intergroup study in Japan.
Matsumoto H, Shimokawa M, Nasu K, Shikama A, Shiozaki T, Futagami M, Kai K, Nagano H, Mori T, Yano M, Sugino N, Fujimoto E, Yoshioka N, Nakagawa S, Shimada M, Tokunaga H, Yamada Y, Tsuruta T, Tasaki K, Nishikawa R, Kuji S, Motohashi T, Ito K, Yamada T, Teramoto N. Matsumoto H, et al. Among authors: shimokawa m. J Gynecol Oncol. 2019 Nov;30(6):e103. doi: 10.3802/jgo.2019.30.e103. J Gynecol Oncol. 2019. PMID: 31576694 Free PMC article.
Predictive and prognostic impact of primary tumor-bearing lobe in nonsmall cell lung cancer patients treated with anti-PD-1 therapy.
Takamori S, Takada K, Shimokawa M, Matsubara T, Haratake N, Miura N, Toyozawa R, Yamaguchi M, Takenoyama M, Yoneshima Y, Tanaka K, Okamoto I, Tagawa T, Mori M. Takamori S, et al. Among authors: shimokawa m. Int J Cancer. 2020 Oct 15;147(8):2327-2334. doi: 10.1002/ijc.33030. Epub 2020 May 18. Int J Cancer. 2020. PMID: 32356560 Free article.
Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab.
Ikoma T, Shimokawa M, Matsumoto T, Boku S, Yasuda T, Shibata N, Kurioka Y, Takatani M, Nobuhisa T, Namikawa T, Kitagawa H, Hanazaki K, Doi K, Shimada T, Tsumura T, Marusawa H, Kanaya S, Morita S, Inokuma T, Nagai H, Yasui H, Satake H. Ikoma T, et al. Among authors: shimokawa m. Cancer Immunol Immunother. 2023 Feb;72(2):427-435. doi: 10.1007/s00262-022-03265-7. Epub 2022 Aug 4. Cancer Immunol Immunother. 2023. PMID: 35927359 Free PMC article.
435 results